Cancer Imaging · 2016 · 46 citations · 19 references
MedicineOncologyRadiologyBiomedical ImagingDiagnostic ImagingDiagnostic RadiologyHepatobiliary ImagingHepatocellular CarcinomaLiver CancerLiver ImagingMagnetic Resonance ImagingMedical ImagingHepatocellular Carcinoma ImagingHepatocellular Carcinoma TreatmentImaging Response EvaluationIntravoxel Incoherent Motion ImagingLiver Tumor ImagingRecist CriteriaSorafenib TherapyTumor Response Evaluation
BACKGROUND: To evaluate the association between the therapeutic outcomes of sorafenib for advanced hepatocellular carcinoma (HCC) and the parameters of intravoxel incoherent motion (IVIM). METHODS: Nine patients were evaluated prospectively. All patients were Child-Pugh score A. The mean dimension of the lesion was 32 mm (range: 15-74 mm). MR images were obtained using a 1.5-Tesla superconductive MRI system. Diffusion-weighted imaging was performed under breath-holding using b-values of 0, 50, 100, 150, 200, 400, and 800 s/mm(2). The following IVIM parameters were calculated: apparent diffusion coefficient, true diffusion coefficient (DC), pseudo-diffusion coefficient, and perfusion fraction. MRI was performed before treatment and at 1, 2, and 4 weeks after beginning treatment. Tumor response at 4 weeks was assessed by CT or MRI using modified RECIST. IVIM parameters of the treatment responders and non-responders were compared. RESULTS: The DC of responders at baseline was significantly higher than that of the non-responders. The sensitivity and specificity, when a DC of 0.8 (10(-3) mm(2)/s) or higher was considered to be a responder, were 100 % and 67 %, respectively. No significant differences were found in the other parameters between the responders and the non-responders. All IVIM parameters of the responders and non-responders did not change significantly after treatment. CONCLUSION: The DC before treatment may be a useful parameter for predicting the therapeutic outcome of sorafenib for advanced HCC.
19
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro et al. · New England Journal of Medicine · 2008 · 13K citations · Full text
Medicine, Oncology, Pharmacology +12
Sorafenib in Advanced Hepatocellular Carcinoma
재연 정 · 2008 · 5.6K citations
Medicine, Oncology, Pharmacology +12
Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging.
Denis Le Bihan, D Lallemand, Michèle Aubin et al. · Radiology · 1988 · 3.2K citations
Liver Cirrhosis: Intravoxel Incoherent Motion MR Imaging—Pilot Study
Alain Luciani, Alexandre Vignaud, Madeleine Cavet et al. · Radiology · 2008 · 608 citations
Diffusion MRI for prediction of response of rectal cancer to chemoradiation
A S K Dzik-Jurasz, Claudia Domenig, Mark George et al. · The Lancet · 2002 · 462 citations